List of Tables
Table 1. Global Human Plasma-derived Hyperimmune Product Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Human Plasma-derived Hyperimmune Product Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Human Plasma-derived Hyperimmune Product Market Competitive Situation by Manufacturers in 2024
Table 4. Global Human Plasma-derived Hyperimmune Product Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Human Plasma-derived Hyperimmune Product Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Human Plasma-derived Hyperimmune Product Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Human Plasma-derived Hyperimmune Product, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Product Type & Application
Table 12. Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Plasma-derived Hyperimmune Product by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Plasma-derived Hyperimmune Product as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Plasma-derived Hyperimmune Product Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Human Plasma-derived Hyperimmune Product Sales by Region (2020-2025) & (K Units)
Table 18. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2020-2025)
Table 19. Global Human Plasma-derived Hyperimmune Product Sales by Region (2026-2031) & (K Units)
Table 20. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2026-2031)
Table 21. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2020-2025)
Table 23. Global Human Plasma-derived Hyperimmune Product Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2026-2031)
Table 25. North America Human Plasma-derived Hyperimmune Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Human Plasma-derived Hyperimmune Product Sales by Country (2020-2025) & (K Units)
Table 27. North America Human Plasma-derived Hyperimmune Product Sales by Country (2026-2031) & (K Units)
Table 28. North America Human Plasma-derived Hyperimmune Product Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Human Plasma-derived Hyperimmune Product Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Human Plasma-derived Hyperimmune Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2020-2025) & (K Units)
Table 32. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2026-2031) & (K Units)
Table 33. Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Human Plasma-derived Hyperimmune Product Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Human Plasma-derived Hyperimmune Product Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Human Plasma-derived Hyperimmune Product Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Human Plasma-derived Hyperimmune Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Human Plasma-derived Hyperimmune Product Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Human Plasma-derived Hyperimmune Product Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Human Plasma-derived Hyperimmune Product Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Human Plasma-derived Hyperimmune Product Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Human Plasma-derived Hyperimmune Product Sales (K Units) by Type (2020-2025)
Table 51. Global Human Plasma-derived Hyperimmune Product Sales (K Units) by Type (2026-2031)
Table 52. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2020-2025)
Table 53. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2026-2031)
Table 54. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2020-2025)
Table 57. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2026-2031)
Table 58. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Type (2020-2025)
Table 59. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Type (2026-2031)
Table 60. Global Human Plasma-derived Hyperimmune Product Sales (K Units) by Application (2020-2025)
Table 61. Global Human Plasma-derived Hyperimmune Product Sales (K Units) by Application (2026-2031)
Table 62. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2020-2025)
Table 63. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2026-2031)
Table 64. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Human Plasma-derived Hyperimmune Product Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2020-2025)
Table 67. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2026-2031)
Table 68. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Application (2020-2025)
Table 69. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Application (2026-2031)
Table 70. CSL Behring Company Information
Table 71. CSL Behring Description and Business Overview
Table 72. CSL Behring Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. CSL Behring Human Plasma-derived Hyperimmune Product Product
Table 74. CSL Behring Recent Developments/Updates
Table 75. Grifols Company Information
Table 76. Grifols Description and Business Overview
Table 77. Grifols Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Grifols Human Plasma-derived Hyperimmune Product Product
Table 79. Grifols Recent Developments/Updates
Table 80. Biotest Company Information
Table 81. Biotest Description and Business Overview
Table 82. Biotest Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Biotest Human Plasma-derived Hyperimmune Product Product
Table 84. Biotest Recent Developments/Updates
Table 85. Kedrion Company Information
Table 86. Kedrion Description and Business Overview
Table 87. Kedrion Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Kedrion Human Plasma-derived Hyperimmune Product Product
Table 89. Kedrion Recent Developments/Updates
Table 90. CBPO Company Information
Table 91. CBPO Description and Business Overview
Table 92. CBPO Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. CBPO Human Plasma-derived Hyperimmune Product Product
Table 94. CBPO Recent Developments/Updates
Table 95. Emergent (Cangene) Company Information
Table 96. Emergent (Cangene) Description and Business Overview
Table 97. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product
Table 99. Emergent (Cangene) Recent Developments/Updates
Table 100. Kamada Company Information
Table 101. Kamada Description and Business Overview
Table 102. Kamada Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Kamada Human Plasma-derived Hyperimmune Product Product
Table 104. Kamada Recent Developments/Updates
Table 105. CNBG Company Information
Table 106. CNBG Description and Business Overview
Table 107. CNBG Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. CNBG Human Plasma-derived Hyperimmune Product Product
Table 109. CNBG Recent Developments/Updates
Table 110. Hualan Bio Company Information
Table 111. Hualan Bio Description and Business Overview
Table 112. Hualan Bio Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Hualan Bio Human Plasma-derived Hyperimmune Product Product
Table 114. Hualan Bio Recent Developments/Updates
Table 115. Shanghai RAAS Company Information
Table 116. Shanghai RAAS Description and Business Overview
Table 117. Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product
Table 119. Shanghai RAAS Recent Developments/Updates
Table 120. Sichuan Yuanda Shuyang Company Information
Table 121. Sichuan Yuanda Shuyang Description and Business Overview
Table 122. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product
Table 124. Sichuan Yuanda Shuyang Recent Developments/Updates
Table 125. ADMA Biologics Company Information
Table 126. ADMA Biologics Description and Business Overview
Table 127. ADMA Biologics Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. ADMA Biologics Human Plasma-derived Hyperimmune Product Product
Table 129. ADMA Biologics Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Human Plasma-derived Hyperimmune Product Distributors List
Table 133. Human Plasma-derived Hyperimmune Product Customers List
Table 134. Human Plasma-derived Hyperimmune Product Market Trends
Table 135. Human Plasma-derived Hyperimmune Product Market Drivers
Table 136. Human Plasma-derived Hyperimmune Product Market Challenges
Table 137. Human Plasma-derived Hyperimmune Product Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Human Plasma-derived Hyperimmune Product
Figure 2. Global Human Plasma-derived Hyperimmune Product Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Human Plasma-derived Hyperimmune Product Market Share by Type: 2024 & 2031
Figure 4. Hepatitis B Immunoglobulins Product Picture
Figure 5. Rabies Immunoglobulins Product Picture
Figure 6. Tetanus Immunoglobulins Product Picture
Figure 7. Rho(D) Immunoglobulins Product Picture
Figure 8. Other Product Picture
Figure 9. Global Human Plasma-derived Hyperimmune Product Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Human Plasma-derived Hyperimmune Product Market Share by Application: 2024 & 2031
Figure 11. Government Institution
Figure 12. Private Sector
Figure 13. Others
Figure 14. Global Human Plasma-derived Hyperimmune Product Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Human Plasma-derived Hyperimmune Product Market Size (2020-2031) & (US$ Million)
Figure 16. Global Human Plasma-derived Hyperimmune Product Sales (2020-2031) & (K Units)
Figure 17. Global Human Plasma-derived Hyperimmune Product Average Price (US$/Unit) & (2020-2031)
Figure 18. Human Plasma-derived Hyperimmune Product Report Years Considered
Figure 19. Human Plasma-derived Hyperimmune Product Sales Share by Manufacturers in 2024
Figure 20. Global Human Plasma-derived Hyperimmune Product Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Human Plasma-derived Hyperimmune Product Players: Market Share by Revenue in Human Plasma-derived Hyperimmune Product in 2024
Figure 22. Human Plasma-derived Hyperimmune Product Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Human Plasma-derived Hyperimmune Product Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2020-2031)
Figure 25. North America Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2020-2031)
Figure 26. United States Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2020-2031)
Figure 29. Europe Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2020-2031)
Figure 30. Germany Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2020-2031)
Figure 37. China Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2020-2031)
Figure 45. Latin America Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Human Plasma-derived Hyperimmune Product Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Human Plasma-derived Hyperimmune Product by Type (2020-2031)
Figure 55. Global Revenue Market Share of Human Plasma-derived Hyperimmune Product by Type (2020-2031)
Figure 56. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Human Plasma-derived Hyperimmune Product by Application (2020-2031)
Figure 58. Global Revenue Market Share of Human Plasma-derived Hyperimmune Product by Application (2020-2031)
Figure 59. Global Human Plasma-derived Hyperimmune Product Price (US$/Unit) by Application (2020-2031)
Figure 60. Human Plasma-derived Hyperimmune Product Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
